Ensysce Biosciences raises $5M in concurrent registered direct offering and warrant exercise

Ensysce Biosciences, Inc.

Gross proceeds of $5M from sale of 3.55M shares (or equivalents) at $0.47 per share and exercise of 7.2M outstanding warrants at reduced price.
Concurrent private placement of unregistered Series A-3 and A-4 warrants to purchase up to 28.7M shares, exercisable after stockholder approval.
Net proceeds to fund TAAP and MPAR programs and supplement recently announced $14M NIH grant for PF614-MPAR.
Existing warrants from November 2023 amended to $0.47 exercise price effective upon closing; stockholder approval required.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.